- •Childhood nasopharyngeal carcinoma cases have high chemoradiothearpy sensitivity and good survival outcomes.
- •The standard high radiation dose (ie. 66-70 Gy) seriously affects the survivors’ quality of life among childhood patients.
- •Identifying a feasible adjustment for radiation dose is of utmost importance in improving the quality of life in children with nasopharyngeal carcinoma.
Patients and methods
Abbreviations:NPC (Nasopharyngeal carcinoma), RT (Radiotherapy), LANPC (locoregionally advanced nasopharyngeal carcinoma), NAC (neoadjuvant chemotherapy), CCRT (concurrent chemoradiotherapy), NCCN (National Comprehensive Cancer Network), CCD (cumulative cisplatin dose), CA-LANPC (children and adolescents with locoregionally advanced nasopharyngeal carcinoma), RD (radiation dose), CR (complete response), PR (partial response), LRFS (locoregional relapse-free survival), DFS (disease-free survival), UICC (Union for International Cancer Control), IMRT (intensity-modulated radiotherapy), MRI (magnetic resonance imaging), PT (primary tumor), LN (lymph nodes), PF (cisplatin plus 5-fluorouracil), TP (docetaxel plus cisplatin), TPF (docetaxel, cisplatin, and 5-fluorouracil), GP (gemcitabine with cisplatin), RTI (radiotherapy interruption), RDstandard (radiation dose of 66-72 Gy), RDreduced (radiation dose of 60-65.9 Gy), EBV (Epstein-Barr virus), CC-CCD (cumulative cisplatin dose during concurrent chemoradiotherapy), NAC-CCD (cumulative cisplatin dose during neoadjuvant chemotherapy), OS (overall survival), DMFS (distant metastasis-free survival), PT-RDstandard (radiation dose of 66-72 Gy to primary tumor), PT-RDreduced (radiation dose of 60-65.9 Gy to primary tumor), LN-RDstandard (radiation dose of 66-72 Gy to lymph nodes), LN-RDreduced (radiation dose of 60-65.9 Gy to lymph nodes)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018; 68: 394-424
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.Int J Cancer. 2019; 144: 1941-1953
- Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.Cancer Res Treat. 2021; 53: 657-670
- Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2020; 18: 873-898
- Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials.Clin Cancer Res. 2018; 24: 1824-1833
- Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy.Int J Radiat Oncol Biol Phys. 2018; 102: 340-352
- The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.Int J Radiat Oncol Biol Phys. 2015; 93: 862-869
- The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.Sci Rep. 2016; 6: 24835
- Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer.Cancer J. 2013; 19: 200-207
- DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.Semin Radiat Oncol. 2015; 25: 237-250
- Impact of late toxicities on quality of life for survivors of nasopharyngeal carcinoma.BMC Cancer. 2014; 14: 856
- Childhood Nasopharyngeal Carcinoma: State-of-the-Art, and Questions for the Future.J Pediatr Hematol Oncol. 2018; 40: 85-92
- Comparison of Long-Term Outcomes and Sequelae Between Children and Adult Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy.Int J Radiat Oncol Biol Phys. 2020; 106: 848-856
- Long-Term Outcomes of Nasopharyngeal Carcinoma in 148 Children and Adolescents.Medicine (Baltimore). 2016; 95: e3445
- Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiation Therapy.Int J Radiat Oncol Biol Phys. 2019; 103: 45-51
- Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.Cancer Sci. 2017; 108: 1640-1647
Yao JJ, Jin YN, Wang SY, Zhang F, Zhou GQ, Zhang WJ, et al The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. BMC Cancer. 2018;18(1):740.
- Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study.Radiother Oncol. 2006; 81: 39-46
- Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.Lancet Oncol. 2012; 13: 163-171
- Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.Lancet Oncol. 2016; 17: 1509-1520
- Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study.Radiother Oncol. 2021; 161: 83-91
- Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study.Cancer Cell Int. 2021; 21: 604
- Nasopharyngeal carcinoma in children and young adults-Beyond 5-year survival.Pediatr Blood Cancer. 2020; 67: e28494
- Radiotherapy dose-volume effects on salivary gland function.Int J Radiat Oncol Biol Phys. 2010; 76: S58-S63
- Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma.Sci Rep. 2015; 5: 13525
- Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.Int J Radiat Oncol Biol Phys. 2007; 68: 1289-1298
- Normal Tissue Complication Probability Model for Radiation-induced Temporal Lobe Injury after Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma.Radiology. 2015; 276: 243-249
- Nasopharyngeal carcinoma in children and adolescents - a single institution experience of 158 patients.Radiat Oncol. 2014; 9: 274
- Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.Eur J Cancer. 2019; 119: 87-96
- Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma.Cancer. 2011; 117: 197-206
- Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.Cancer. 2012; 118: 4892-4900
- Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH).Cancer. 2005; 104: 1083-1089